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Abstract
Background: Extracorporeal membrane oxygenation (ECMO) is a life-saving modality used in the management of
cardiopulmonary failure that is refractory to conventional medical and surgical therapies. The major problems
clinicians face are bleeding and clotting, which can occur simultaneously. To discern the impact of pulmonary
injury and ECMO on the host’s haemostatic response, we developed an ovine model of smoke-induced acute
lung injury (S-ALI) and ECMO. The aims of this study were to determine if the ECMO circuit itself altered
haemostasis and if this was augmented in a host with pulmonary injury.
Methods: Twenty-seven South African meat merino/Border Leicester Cross ewes underwent instrumentation. Animals
received either sham injury (n = 12) or S-ALI (n = 15). Control animal groups consisted of healthy controls (ventilation
only for 24 h) (n = 4), ECMO controls (ECMO only for 24 h) (n = 8) and S-ALI controls (S-ALI but no ECMO for
24 h) (n = 7). The test group comprised S-ALI sheep placed on ECMO (S-ALI + ECMO for 24 h) (n = 8). Serial
blood samples were taken for rotational thromboelastometry, platelet aggregometry and routine coagulation
laboratory tests. Animals were continuously monitored for haemodynamic, fluid and electrolyte balances and
temperature. Pressure-controlled intermittent mandatory ventilation was used, and mean arterial pressure was
augmented by protocolised use of pressors, inotropes and balanced fluid resuscitation to maintain mean
arterial pressure >65 mmHg.
Results: Rotational thromboelastometry, platelet aggregometry and routine coagulation laboratory tests demonstrated
that S-ALI and ECMO independently induced changes to platelet function, delayed clot formation and reduced clot
firmness. This effect was augmented with the combination of S-ALI and ECMO, with evidence of increased
collagen-induced platelet aggregation as well as changes in factor VIII (FVIII), factor XII and fibrinogen levels.
Conclusions: The introduction of an ECMO circuit itself increases collagen-induced platelet aggregation,
decreases FVIII and von Willebrand factor, and induces a transient decrease in fibrinogen levels and function
in the first 24 h. These changes to haemostasis are amplified when a host with a pre-existing pulmonary injury is
placed on ECMO. Because patients are often on ECMO for extended periods, longer-duration studies are required to
characterise ECMO-induced haemostatic changes over the long term. The utility of point-of-care tests for guiding
haemostatic management during ECMO also warrants further exploration.
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Background
Extracorporeal membrane oxygenation (ECMO) is a life-
saving modality used in the management of cardiopul-
monary failure that is unresponsive to conventional
medical and surgical therapies. Despite its benefits,
survival rates for ECMO are only 84%, 67% and 66% when
used for respiratory failure and 62%, 67% and 56% when
used for cardiac failure in neonates, paediatric patients
and adults, respectively [1]. Bleeding events remain a
common and serious complication during ECMO, occur-
ring in approximately 30% of patients [2–4]. Authors of
some reports have proposed that contact between the
patient’s blood and the ECMO circuit can lead to activa-
tion of the coagulation, fibrinolysis and complement path-
ways [5]. The shift to a pro-coagulant state appears to be
mediated primarily by thrombin, whilst there is an exces-
sive fibrinolytic tendency mediated by plasmin, with the
result being consumption of clotting factors, impaired
platelet function, thrombocytopenia, and fibrinolysis [5].
The goal of the clinician is to minimise bleeding and trans-
fusion requirements whilst avoiding micro- or macro-
thrombus formation in the circuit and within the
patient’s cardiovascular system [6]. This tightrope is a
dynamic process; hence, a more complete understand-
ing of how haemostasis is altered may improve bleeding
management strategies and thus to reduce morbidity
and mortality.
Unfractionated heparin is the systemic anti-coagulant
most widely used during ECMO and is monitored pri-
marily by activated clotting time (ACT). Viscoelastic
tests using rotational thromboelastometry (ROTEM®)
are gaining popularity because they assess whole blood
coagulation and thus provide information on the dynam-
ics of clot development, stabilisation and dissolution. A
number of small studies suggest that ROTEM®-guided
coagulation management could reduce bleeding episodes
in ECMO patients [7, 8]. Whole blood platelet aggrego-
metry using the cobas Multiplate® (Roche Diagnostics,
Rotkreuz, Switzerland) is also increasing in use with a
recent study demonstrating decreased platelet aggrega-
tion in ECMO patients [8].
Patients who require ECMO are critically ill, thus
making it difficult to discern the relative contributions
of a patient’s underlying pathology from the insult of
the ECMO circuit per se. We hypothesised that the
ECMO circuit itself alters haemostasis and that this be-
comes more pronounced in the presence of a pre-
existing lung injury. To discern the ECMO effect from
that of the underlying illness, we used an established
ovine model of lung injury and placed the animal on
ECMO support. Haemostasis was monitored using con-
ventional coagulation assays, thromboelastometry and
platelet aggregometry to determine how each physio-
logical insult alters coagulation in this scenario.
Methods
Extracorporeal membrane oxygenation ovine model
This study was approved by the animal research and
ethics committee of the Queensland University of Tech-
nology and the University of Queensland (approval num-
bers 1100000053 and 1000000025) and adhered to the
Australian Code for the Care and Use of Animals for
Scientific Purposes, Eighth Edition, 2013 (the code), of the
National Health and Medical Research Council. A total of
27 South African meat merino (SAMM)/Border Leicester
Cross ewes weighing between 39 and 58 kg (mean
49.5 kg) were randomly divided into four groups. Animals
received either sham injury (n = 12) or smoke-induced
acute lung injury (S-ALI) (n = 15) as detailed previously
[9]. Sham injury animals were divided into healthy con-
trols (ventilation only for 24 h) (n = 4) and ECMO con-
trols (ECMO only for 24 h) (n = 8). S-ALI animals
were divided into controls (S-ALI only, no ECMO for
24 h) (n = 7) and the test group of S-ALI + ECMO (n = 8)
for 24 h. ECMO was instituted as per our previously vali-
dated model [10]. Briefly, animals placed on ECMO had a
21- to 23-French femoral venous cannula (Medtronic,
Minneapolis, MN, USA) inserted into the internal jugular
vein and positioned in the distal inferior vena cava (access
cannula). A 19- to 21-French venous cannula (Medtronic)
was placed at the superior vena cava-right atrium junction
(return cannula). Intra-cardiac echocardiography was used
to confirm the cannula position. A Jostra ROTAFLOW
centrifugal pump (Maquet Cardiopulmonary, Rastatt,
Germany) was used, and target flow rates of 3–4 L/minute
were maintained. Porcine mucous heparin (1000 U; Pfizer
Australia, West Ryde, Australia) was added to the circuit,
and a heparin infusion was commenced at 4 U/kg/h to
obtain a target ACT between 220 and 300 seconds. Sheep
were continuously monitored for haemodynamics, fluid
and electrolyte balances, and temperature. Pressure-
controlled mandatory ventilation based on previous ovine
models was used [11, 12]. An arterial partial pressure of
carbon dioxide of approximately 30 mmHg and arterial
partial pressure of oxygen >80 mmHg were managed via
ECMO gas sweep. Mean arterial pressure was augmented
by protocolised use of pressors, inotropes and balanced
fluid resuscitation to maintain mean arterial pressure
>65 mmHg. Bolus fluids and increased maintenance fluids
(up to 500 ml/h) were administered when a persistent
decrement in ECMO blood flows was observed and other
potential causes for the same were excluded.
Blood sampling
Arterial blood samples and blood gas measurements
(temperature, pH, ionised calcium) were collected at
baseline; 15 minutes post-S-ALI (or sham injury) (S0),
before ECMO commencement (S2); and 1, 2, 6, 12, 18
and 24 h post-ECMO. Blood samples were also taken for
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ROTEM® analysis, full blood examination (FBE) and
Multiplate® whole blood platelet aggregometric testing.
Samples for routine coagulation tests were centrifuged
twice (15 minutes, 4 °C, 3000 × g) to obtain platelet-poor
plasma and were subsequently stored at −80 °C until
further analysis.
Full blood examination and routine coagulation tests
An FBE using the veterinary mode of the AcT diff™
haematology analyser (Beckman Coulter Australia Pty
Ltd, Lane Cove West, Australia) was performed to assess
the white cell count (WCC), red cell count (RCC),
haemoglobin (Hb), haematocrit (Hct) and platelet count.
Prothrombin time (PT), activated partial thromboplastin
time (aPTT), factor VIII (FVIII) and FXII, anti-thrombin
(AT), fibrinogen using the Clauss method, protein C, von
Willebrand factor antigen (vWAg), thrombin clotting time
(TCT) and D-dimer were performed on the ACL TOP®
analyser (Instrumentation Laboratory/Werfen Australia,
Artarmon, Australia) or the Stago STA-R Evolution ana-
lyser (Diagnostica Stago, Doncaster, Australia) following
the manufacturer’s instructions. ACT was measured in
fresh whole blood using kaolin tubes with the HEMO-
CHRON® 401 coagulation analyser (Soma Technology,
Bloomfield, CT, USA).
Whole blood platelet function (Multiplate®)
Whole blood platelet aggregometry was measured by
change in impedance and expressed in aggregation units
using the Multiplate® 5.0 platelet function analyser.
Hirudin-anticoagulated blood was tested using adenosine
diphosphate (ADP; 6.4 μmol/L) and collagen (3.2 μg/ml)
agonists [13, 14].
ROTEM®
Whole blood clot formation profiles were recorded by
ROTEM® (Haemoview Diagnostics, Brisbane, Australia)
with the EXTEM (thromboplastin-initiated coagulation),
INTEM (contact factor-initiated coagulation), FIBTEM
(thromboplastin-initiated coagulation with the platelet
inhibitor cytochalasin D) and HEPTEM (contact factor-
initiated coagulation with heparinase) activating reagents
in accordance with the manufacturer’s instructions.
Parameters evaluated included clotting time (CT), clot for-
mation time (CFT) and maximum clot firmness (MCF).
Statistical analysis
To determine the effect of the experimental group on
each outcome, a mixed effects linear regression model
was fitted with random effects for sheep and time (within
sheep). Potential confounders included the laboratory
Fig. 1 The effect of ECMO on physiological parameters. Temperature remained constant a, while S-ALI controls and S-ALI + ECMO animals had a
decreased pH b. Ionised calcium levels c and the circuit flow rate d were decreased in S-ALI + ECMO compared with healthy controls. Data are
presented as mean ± SEM. *P < 0.05, ***P < 0.001 versus healthy controls. n = 4 healthy controls, n = 8 ECMO controls, n = 7 S-ALI controls, n = 8 S-
ALI + ECMO. ECMO Extracorporeal membrane oxygenation, S-ALI Smoke-induced acute lung injury, B Baseline
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where routine and specialised coagulation testing was per-
formed, weight of the animal at baseline, fluid balance and
the ratio of INTEM-CT to HEPTEM-CT (used as a proxy
measure to adjust for potential confounding due to
heparin dosage). Eligible confounders with univariable
P values <0.2 were entered into a multivariable
model, and a stepwise backwards elimination process
was applied until all variables remained significant at
the 0.05 level. Statistical analyses were performed
using the STATATM 13 statistical software package
(StataCorp, College Station, TX, USA).
Results
Physiological, haematological and routine coagulation
parameters
Sheep body temperature remained constant throughout
the experiment (Fig. 1a). Significant decreases in pH
(Fig. 1b) were seen in the S-ALI control (P < 0.001) and
S-ALI + ECMO groups (P < 0.05) compared with healthy
controls, although this was still within the normal range
for ovine pH (7.32–7.5). S-ALI + ECMO groups also had
decreased ionised calcium levels (P < 0.001) (Fig. 1c) and
a significantly decreased circuit flow rate (P < 0.05)
(Fig. 1d) compared with healthy controls. The mean and
SD of all haematological and plasma-based coagulation
parameters at selected time points are detailed in Table 1.
Baseline measurements for FBE as well as routine and
specialised coagulation tests did not differ significantly
across the experimental groups. Results from each group
were compared with those of the healthy control group.
WCC (P = 0.004), RCC (P = 0.01) and Hb (P < 0.001) in-
creased in the S-ALI controls. In contrast, WCC (P = 0.01),
RCC (P < 0.001) and Hb (P < 0.001) levels were lower in
the ECMO controls. S-ALI + ECMO animals also had
lower WCC (P < 0.001). Platelet count remained un-
changed across all groups. A prolonged PT was ob-
served in both S-ALI controls (P < 0.001) and S-ALI +
ECMO (P < 0.001) groups after 12 h of ECMO. aPTT,
TCT and D-dimer did not differ significantly in any groups
compared with healthy controls. Fibrinogen, FVIII and
vWAg levels were lower in ECMO controls (P < 0.001).
Fibrinogen, AT, FXII and protein C levels were lower
in S-ALI controls (P < 0.001). With the combination
of S-ALI + ECMO, there were reductions in coagulation
factors FVIII and FXII as well as fibrinogen and vWAg.
The levels of naturally occurring anti-coagulants AT and
protein C were also lower in this group (P < 0.001). Pre-
dicted marginal means with 95% CIs over experimental
group for measures of interest are shown in Table 2 along
Table 1 Routine and specialised haemostatic parameters by experimental group at selected time points
Ventilation only S-ALI control ECMO control S-ALI + ECMO
B 24 h B 24 h B 24 h B 24 h
Full blood examination
WCC, ×109/L 9.8 (3.1) 10.2 (2.2) 7.8 (2.1) 21.8 (8.3)a 7.0 (2.2) 7.9 (1.7)a 6.6 (1.2) 9.1 (3.8)a
RCC, ×1012/L 8.7 (0.68) 6.2 (0.6) 8.5 (0.78) 8.9 (1.36)a 8.0 (1.2) 4.8 (0.54)a 8.3 (0.87) 7.3 (1.2)
Hb, g/L 97.8 (9.1) 70.3 (6.1) 96.1 (9.4) 99.1 (12)a 89.3 (12) 54.3 (5.4)a 93.4 (11) 83.5 (12)
Hct 0.28 (0.02) 0.20 (0.02) 0.28 (0.03) 0.29 (0.04)a 0.26 (0.04) 0.16 (0.01)a 0.28 (0.03) 0.24 (0.04)
PLT, ×109/L 341 (173) 190 (110) 355 (186) 203 (111) 471 (95) 260 (80) 364 (140) 199 (60)
Routine coagulation tests
PT, seconds 14.5 (1) 17.3 (1) 15.9 (1.1) 34.4 (5.4)a 12.9 (0.6) 17.4 (2.1) 14.3 (0.9) 35 (6.7)a
aPTT, seconds 33 (6) 139 (76) 31 (6) 165 (42) 26 (4.6) 122 (64) 30 (6) 158 (57)
Fibrinogen, g/L 2.5 (0.54) 3.5 (0.13) 2.1 (0.62) 2.5 (0.34)a 2.9 (0.47) 2.6 (0.16)a 3.0 (0.97) 1.5 (0.5)a
D-dimer, ng/ml 215 (85) 198 (70) 146 (44) 139 (82) 435 (192) 343 (217) 406 (213) 213 (136)
TCT, seconds 13 (0) 21 (7) 13 (0) 81 (84) 12 (1) 156 (81) 13 (1) 44 (69)
Specialised coagulation tests
FVIII, % 1531 (413) 1390 (414) 1347 (417) 1544 (238) 891(235) 408 (51)a 904 (166) 531 (242)a
FXII, % 103 (17.7) 75 (10) 96 (30.9) 29 (11.5)a 151 (37.7) 67 (12.4) 107 (20.2) 16 (6.7)a
Protein C, % 21.5 (2.5) 21.5 (1.3) 21 (7.4) 12.1 (3.2) 55 (13.4) 50 (11.2) 46 (11.4) 14 (4.5)a
vWAg, % 136 (22.3) 130 (25.8) 96 (31.9) 140 (18.2) 94 (47.6) 88 (10.9)a 129 (30) 96 (25.3)a
AT, % 85.8 (7.3) 58.3 (6.6) 84.1 (3.9) 27.1 (3.2)a 93.7 (8.8) 62.7 (6) 92.3 (1.9) 22 (4.3)a
Abbreviations: aPTT Activated partial thromboplastin time, AT Anti-thrombin, B baseline, ECMO Extracorporeal membrane oxygenation, FVIII Factor VIII, FXII Factor
XII, Hb Haemoglobin, Hct Haematocrit, PLT Platelets, PT Prothrombin time, RCC Red cell count, S-ALI Smoke-induced acute lung injury, TCT Thrombin clotting time,
vWAg von Willebrand factor antigen, WCC White cell count
Data are presented as mean (±SD)
aP < 0.05 over time vs ventilation only
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with overall Wald P values derived from mixed effects
regression models.
Platelet function (Multiplate®)
Relative to healthy controls, collagen-induced platelet func-
tion was significantly higher in S-ALI controls (P = 0.001),
ECMO controls (P < 0.001) and S-ALI + ECMO (P < 0.001)
experimental groups (Fig. 2a). There was no significant dif-
ference in ADP platelet aggregation across any of the ex-
perimental groups (Fig. 2b).
Thromboelastometry
S-ALI controls (P < 0.001) and the S-ALI + ECMO group
(P = 0.03) had a significantly lower INTEM-MCF (Fig. 3a)
than healthy controls. Both S-ALI controls (P = 0.007)
and S-ALI + ECMO (P < 0.001) animals had a significantly
lower HEPTEM-MCF (Fig. 3b). There was no significant
difference in INTEM or HEPTEM-CFT across any of the
experimental groups (data not shown). EXTEM-CFT was
extended in S-ALI controls (P = 0.011) and further pro-
tracted in S-ALI + ECMO (P < 0.001) experimental ani-
mals (Fig. 3c). In addition, the overall clot quality as
measured by the EXTEM-MCF was also lower in S-ALI
controls (P = 0.031) and further decreased in S-ALI +
ECMO (P < 0.001) (Fig. 3d).
Fibrinogen levels in all three experimental groups
(P < 0.001) were significantly lower than in healthy
controls (Fig. 4a). FIBTEM-CFT was prolonged in
both S-ALI controls (P = 0.016) and the S-ALI + ECMO
group (P = 0.001) (Fig. 4b). FIBTEM-MCF was lower in S-
ALI controls (P < 0.001) and ECMO controls (P = 0.001)
and was further reduced in S-ALI + ECMO (P < 0.001)
groups (Fig. 4c).
Discussion
In clinical practice, it is the critically ill who are placed
on ECMO. This ovine smoke injury and ECMO model
has revealed that the introduction of an ECMO circuit
alone leads to an increase in collagen-induced platelet
aggregation and a reduction in the levels of coagulation
factors FVIII, FXII and fibrinogen. When a host with S-
ALI is placed on ECMO, these haemostatic alterations
are augmented.
Studies on the impact of ECMO on platelet number
document variable results. A number of case series
and reviews suggest the ECMO circuit may lead to
Table 2 Predicted marginal mean values and 95% CIs for haemostatic parameters, by experimental group and overall Wald P values
derived from mixed effects regression models
Ventilation only S-ALI control ECMO control S-ALI + ECMO Wald P value
WCC 8.4 (6.8–9.9) 5.5 (4.4–6.7) 6.0 (4.8–7.2) 4.9 (3.8–6) 0.004
RCC 6.9 (6.3–7.5) 7.3 (6.9–7.8) 5.0 (4.5–5.5) 6.2 (5.7–6.6) <0.001
Hb 75 (70–81) 87 (83–91) 55 (50–60) 73 (69–77) <0.001
PLT 195 (121–269) 248 (188–309) 238 (185–290) 207 (155–260) 0.609
PT 16 (13.4–18.6) 20 (17.7–22.2) 18.9 (16.7–21) 23.7 (22.1–25.3) 0.007
aPTT 113 (89–137) 117 (96–139) 100 (80–119) 124 (106–141) 0.164
TCT 68 (36–99) 96 (69–122) 159 (133–184) 104 (82–127) 0.063
D-dimer 211 (98–324) 157 (71–242) 332 (232–432) 276 (195–358) 0.852
Fib(C) 2.7 (2.4–3) 2.0 (1.7–2.3) 2.2 (1.9–2.4) 1.4 (1.2–1.6) <0.001
FVIII 1161 (1016–1307) 1082 (956–1208) 529 (410–647) 505 (415–595) <0.001
FXII 70 (59–81) 22 (13–31) 63 (55–72) 13 (6–20) <0.001
vWAg 135 (120–151) 130 (118–142) 92 (79–106) 103 (92–114) <0.001
Protein C 23 (17–29) 15 (10–20) 51 (47–56) 14 (9–18) <0.001
INTEM-CFT 323 (154–492) 332 (179–486) 211 (115–306) 235 (121–348) 0.468
INTEM-MCF 67 (55–79) 52 (41–63) 64 (57–71) 58 (52–64) <0.001
HEPTEM-CFT 92 (35–149) 89 (46–132) 136 (85–187) 105 (65–146) 0.5416
HEPTEM-MCF 69 (65–74) 67 (63–71) 70 (65–74) 60 (57–63) 0.001
EXTEM-CFT 108 (87–130) 144 (127–160) 105 (90–121) 179 (164–194) <0.001
EXTEM-MCF 75 (71–78) 71 (68–74) 71 (68–74) 63 (61–65) <0.001
FIBTEM-MCF 29 (26–33) 23 (20–26) 23 (20–26) 16 (14–19) <0.001
Abbreviations: aPTT Activated partial thromboplastin time, AT Anti-thrombin, CFT Clot formation time, ECMO Extracorporeal membrane oxygenation, Fib(C) Clauss
fibrinogen, FVIII Factor VIII, FXII Factor XII, Hb Haemoglobin, MCF Maximum clot firmness, PLT Platelets, PT Prothrombin time, RCC Red cell count, S-ALI Smoke-induced
acute lung injury, TCT Thrombin clotting time, vWAg von Willebrand factor antigen, WCC White cell count
Data are presented as predicted mean (95% CI)
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thrombocytopenia through platelet consumption [15–17];
however, two recent studies demonstrated that ECMO is
not associated with decreased platelet numbers [18, 19].
Consistent with these latter reports, we observed no
significant decrease in platelet numbers in our ovine
ECMO model.
While platelet numbers were unaffected by ECMO, it
is possible that haemostasis in our ovine ECMO model
may have been impacted by perturbations in platelet
function. To investigate this possibility, we conducted
whole blood platelet function assays. We and others
have previously demonstrated the utility of human plate-
let function assays in the ovine setting [13, 14]. The
platelet ADP response in SAMM/Border Leicester Cross
sheep is comparable to that of humans [14], and in our
study, there was no change with ADP-induced platelet
aggregation in any of the sheep groups compared with
healthy controls. In contrast, researchers in several stud-
ies have reported an impaired platelet response with
ADP in adults [8, 20] as well as children on ECMO [21].
Patients are often on ECMO for extended time periods,
and because our study involved only a 24-h observation
period, it is conceivable that ADP-dependent platelet
dysfunction may develop with prolonged exposure.
While the collagen response in SAMM/Border Leicester
Cross sheep is lower than that of humans [14], we
observed significant increases in collagen-triggered
platelet function with S-ALI and ECMO individually and
sequentially. The shear stress from the ECMO circuit is
thought to damage endothelial cells, thus exposing colla-
gen and inducing platelet aggregation [22]. In addition,
shear stress has been shown to induce amplification of
platelet micro-particle production and shedding [23], as
well as to prime platelets for faster activation [24].
SAMM/Border Leicester Cross sheep have similar levels
of von Willebrand factor (vWF) to humans, but they have
significantly higher levels of FVIII [14]. Results from this
study demonstrate that while S-ALI does not affect circu-
lating FVIII or vWF, the introduction of the ECMO circuit
in both ECMO controls and S-ALI + ECMO resulted in a
significant reduction in vWF and FVIII levels. Because our
analysis was corrected for fluid administration, this effect
cannot be attributed to haemodilution alone. Rather, ex-
posure of blood to the increased shear stress of the ECMO
circuit may be causative. Increased shear stress, as seen in
ventricular assist devices (VADs), total artificial hearts and
aortic valve stenosis, has been reported to cause alter-
ations in the configuration of vWF and reduced levels of
high-molecular-weight multimers (HMWM) of vWF [25].
Patients on long-term VADs have been reported to de-
velop acquired von Willebrand syndrome, which has been
linked to the loss of HMWM [26, 27]. In a study of eight
ECMO patients, researchers reported relatively stable
FVIII levels but a decreased ristocetin cofactor to vWF ra-
tio, indicating the possible loss of HMWM of vWF [17,
28]. While no change to FVIII levels has been recorded in
human studies, we speculate that the higher levels of FVIII
in sheep enabled us to detect this change more easily.
Because ROTEM is routinely used to provide rapid re-
sults for managing bleeding in our intensive care unit [29],
we also applied it to assess whole blood coagulation in this
model. The shortened INTEM CTs in both the ECMO
groups are consistent with reduced FVIII and vWF. As ex-
pected with heparin administration, prolongation of the
aPTT did not change significantly across groups. With
respect to measures of the extrinsic pathway, both S-ALI
controls and S-ALI + ECMO samples demonstrated an in-
crease in PT to more than double the baseline time after
24 h of ECMO support. These results suggest that whole
blood coagulation assays (thromboelastometry) may be
more informative and sensitive than plasma-based assays
(aPTT and PT) when monitoring ECMO patients [30].
Our results showed that both S-ALI and ECMO indi-
vidually compromised fibrinogen function, and the com-
bined insult of S-ALI + ECMO produced a cumulative
effect. Interestingly, serial monitoring revealed a transient
early decrease in fibrinogen level and function following
Fig. 2 Platelet aggregometric function for each group of animals.
a Collagen-induced AUC was significantly higher in S-ALI controls, ECMO
controls and S-ALI + ECMO groups, while b ADP was not significantly
different. Data are presented as mean ± SEM. ***P< 0.001 versus healthy
controls. n= 4 healthy controls, n= 8 ECMO control, n= 7 S-ALI controls,
n= 8 S-ALI + ECMO. ADP Adenosine diphosphate; B Baseline, ECMO
Extracorporeal membrane oxygenation, S-ALI Smoke-induced acute
lung injury
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the initiation of ECMO, which begins normalising after
12 h. Fibrinogen is one of the first plasma proteins to be
adsorbed onto the ECMO circuit and has been shown to
be associated with platelet consumption [31]. Whether
fibrinogen levels return to baseline levels and function
after 24 h remains to be investigated.
D-Dimer levels did not change significantly in any of
the groups, but protein C and AT levels decreased with
time in both S-ALI controls and S-ALI + ECMO. Studies
in patients with burn injuries and inhalational trauma
showed increased thrombin-AT complexes and fibrin
degradation products with decreased levels of protein C
and AT consistent with pulmonary coagulopathy [32]. A
series of ovine models of smoke inhalation injury have
shown that aerosolised anticoagulants such as heparin,
recombinant human AT and recombinant activated pro-
tein C reduce airway obstruction and improve oxygen-
ation [33–35]. Because this was a 24-h model, we were
unable to determine if the compromise to the extrinsic
pathway continued, plateaued or recovered with time.
As with any animal model, there were species-
associated limitations. While SAMM/Border Leicester
Cross sheep have aPTT, PT, TCT and fibrinogen
levels similar to those in humans, they have signifi-
cantly higher FVIII and half the protein C levels. In
addition, coagulation measurements were performed
using assays optimised for humans and were refer-
enced against human calibration plasma with assigned
values traceable to National Institute for Biological
Standards and Control standards. The 24-h duration
of the experiment was also a limitation because most
patients remain on ECMO support for days to weeks.
The complexity of the study and the high cost of the
experiment prevented us from extending the duration
of ECMO. Longer-duration studies are required to
determine if the observed haemostatic changes are
transient or stable or whether they will escalate.
The predominant challenge for a clinician caring for a
patient on ECMO is making an informed assessment of
the bleeding and clotting risks of each patient. Assessment
of the patient’s haemostasis includes consideration of the
pathophysiology, degree of organ failures and extent of tis-
sue trauma during cannulation. Thus, a holistic approach
to haemostatic management is needed to balance all these
factors. This incremental ovine model enabled us to show
that S-ALI + ECMO induced decreases in FVIII, FXII and
Fig. 3 The effect of ECMO on INTEM, HEPTEM and EXTEM parameters. INTEM and HEPTEM-MCF a and b in the S-ALI controls and S-ALI + ECMO
groups was significantly lower than in healthy controls. c EXTEM-CFT was prolonged in both S-ALI controls and S-ALI + ECMO. d EXTEM-MCF was
subsequently lower in both S-ALI controls and S-ALI + ECMO. Data are presented as mean ± SEM. *P < 0.05, ***P < 0.001 versus healthy controls.
n = 4 healthy controls, n = 8 ECMO controls, n = 7 S-ALI controls, n = 8 S-ALI + ECMO. B Baseline, CFT Clot formation time, ECMO Extracorporeal
membrane oxygenation, MCF Maximum clot firmness, S-ALI Smoke-induced acute lung injury
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vWAg and altered platelet response. While factor assays
cannot be performed quickly, both ROTEM and whole
blood platelet aggregometry provide rapid information on
whole blood coagulation and thus may be used to guide
the use of blood product support, factor replacement,
anti-coagulation therapy and anti-fibrinolytics. Future re-
search on the utility of ROTEM and whole blood platelet
aggregometry of ECMO patients is required to determine
their efficacy to support real-time haemostatic manage-
ment in this cohort.
Conclusions
This animal model enabled us to demonstrate that the
introduction of an ECMO circuit itself alters haemosta-
sis, specifically by increasing collagen-induced platelet
aggregation and reducing levels of fibrinogen, FVIII and
vWF. In addition, the model demonstrated that these
haemostatic perturbations are amplified in a host with
pre-existing pulmonary injury. Thus, the introduction of
ECMO support on its own alters haemostasis in the first
24 h. Longer-duration studies are required to character-
ise the haemostatic changes beyond this time. Additional
efficacy studies are also required to assess the potential
of point-of-care coagulation and platelet function tests
for guiding haemostatic management during ECMO.
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